Ozanimod
Overview
Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator, used for the treatment of relapsing forms of multiple sclerosis and ulcerative colitis. By modulating S1P receptors, it reduces lymphocyte migration into the central nervous system and other tissues.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Ozanimod expires 30 Sept 2038 and exclusivity 30 Aug 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Ozanimod? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.